Semax vs Selank: A Deep Comparison of Russia's Two Flagship Nootropic Peptides

This article is for educational and research purposes only. These compounds are not approved medicines in Australia. This does not constitute medical advice.

Russia's contributions to peptide neuropharmacology are underappreciated in Western research circles. While much of the Anglophone nootropic literature focuses on racetams, natural adaptogens, or pharmaceutical cognitive enhancers developed in the United States or Europe, two short peptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences have accumulated a substantial body of clinical and preclinical evidence over several decades: Semax and Selank. They are often mentioned together, frequently compared, and — in certain research protocols — used in combination. Yet they are mechanistically distinct in ways that matter considerably when selecting one over the other for a specific research question.

This article provides a rigorous comparison of both compounds: their structural origins, receptor pharmacology, neurochemical footprint, documented effects, research base, and the conditions under which each is most likely to be the appropriate investigative tool.

Structural Origins and Design Logic

Semax: The ACTH Fragment

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is derived from the 4–7 fragment of adrenocorticotropic hormone (ACTH 4-7), with the addition of a C-terminal Pro-Gly-Pro tripeptide sequence to extend its half-life and enhance penetration of the blood-brain barrier. The parent sequence — ACTH 4-7 — is the minimal fragment of ACTH responsible for its cognitive and neuroprotective effects, stripped of the adrenal steroidogenic activity that makes full ACTH pharmacologically problematic.

The Pro-Gly-Pro extension is not decorative. This tripeptide is itself bioactive: it is a fragment of collagen and is found in the brain as a cleavage product of alpha-2 macroglobulin. It has independent anxiolytic properties and may contribute to Semax's broader neurochemical profile beyond the ACTH-derived core.

Selank: The Tuftsin Analogue

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its parent compound is tuftsin — a tetrapeptide (Thr-Lys-Pro-Arg) naturally produced by the spleen as a cleavage product of IgG, where it plays a role in immune modulation and macrophage activation. The same Pro-Gly-Pro extension used in Semax was appended to tuftsin to produce Selank, again for metabolic stability.

Tuftsin itself has documented anxiolytic and antidepressant effects in animal models, and its cognitive-modulating properties were identified before Selank was synthesised. The structural similarity between Semax and Selank — both ending in the Pro-Gly-Pro sequence, both heptapeptides — reflects a shared design philosophy from the same research group, even though their parent molecules come from entirely different biological contexts.

Mechanisms of Action

Semax: Stimulatory, Catecholaminergic, BDNF-Upregulating

Semax operates through several interconnected mechanisms:

BDNF and neurotrophin upregulation. The most replicated finding in Semax research is its capacity to rapidly increase brain-derived neurotrophic factor (BDNF) expression in the hippocampus and frontal cortex. This effect has been demonstrated at the mRNA level within hours of administration in rodent models and is thought to underlie its effects on synaptic plasticity, learning consolidation, and neuroprotection. BDNF and neuroplasticity provides an in-depth treatment of why BDNF upregulation is considered one of the most significant targets in cognitive neurochemistry.

Dopaminergic and serotonergic modulation. Semax increases dopamine and serotonin turnover in the striatum and prefrontal cortex. Dopaminergic effects are likely to underlie the motivational and attentional enhancement that research subjects and clinicians consistently report. The compound has also been shown to increase the expression of dopamine receptors D1 and D2 in certain brain regions, which may explain why its effects on motivation appear sustained rather than acutely stimulant-like.

Cholinergic enhancement. Semax upregulates the high-affinity choline transporter (CHT1) in cortical neurons, increasing the capacity for acetylcholine synthesis. This places it in a mechanistically interesting category: a peptide that enhances both catecholaminergic tone and cholinergic substrate availability simultaneously — a combination that few conventional nootropics achieve.

Enkephalin system modulation. Research from the Institute of Molecular Genetics has documented Semax's effects on the endogenous enkephalin system — specifically, it increases the expression of preproenkephalin mRNA, which may contribute to both its analgesic effects and the regulation of dopamine release through opioid-dopamine interaction.

Anti-inflammatory and neuroprotective actions. Semax reduces the expression of proinflammatory cytokines in the brain and has demonstrated neuroprotective effects in models of ischaemia, hypoxia, and excitotoxicity. Russian clinical research has investigated it specifically in the context of acute ischaemic stroke.

The overall pharmacological character of Semax is therefore stimulatory, pro-dopaminergic, and pro-cholinergic — increasing arousal, drive, and the capacity for focused cognitive effort.

Selank: Anxiolytic, GABAergic, BDNF-Modulating

Selank's mechanisms are substantially different:

GABAergic modulation. Selank's primary anxiolytic effect is mediated through the GABA-A receptor complex, where it acts as a positive allosteric modulator at benzodiazepine binding sites without causing the receptor downregulation or dependence characteristic of classical benzodiazepines. This mechanism has been confirmed in competitive binding assays and in animal models where GABAergic antagonists block Selank's anxiolytic effects.

BDNF modulation (context-dependent). Like Semax, Selank modulates BDNF — but the nature of the modulation differs. Selank normalises BDNF expression in stress conditions rather than robustly upregulating it in baseline states. In animals subjected to chronic unpredictable stress, Selank restores BDNF levels that have been suppressed by the stress response. This restorative, homeostatic action is mechanistically different from Semax's more pronounced upregulatory effect.

Enkephalinase inhibition. Selank inhibits enkephalinase, the enzyme responsible for degrading met-enkephalin in the brain. The resulting increase in endogenous enkephalin levels contributes to both anxiolytic effects (through opioid receptor-mediated modulation of the stress response) and to the regulation of dopamine release in the mesolimbic pathway.

Serotonin modulation. Selank increases serotonin turnover and has been shown to upregulate expression of the serotonin transporter (SERT) in certain regions under stress conditions. This serotonergic component may explain its utility in anxiety and stress contexts, where serotonin deficiency is a common finding.

Immune modulation (from tuftsin heritage). Retaining properties from its tuftsin parent, Selank modulates immune function — increasing natural killer cell activity and modulating cytokine profiles. While the cognitive relevance of this is indirect, it may contribute to Selank's observed effects on the brain-immune axis under conditions of stress-induced immunosuppression.

The overall pharmacological character of Selank is therefore anxiolytic, GABAergic, and homeostatic — reducing anxiety, normalising stress-disrupted neurochemistry, and enabling cognitive performance through the removal of anxiety-driven interference rather than direct stimulation.

Research Base: Russian and Eastern European Clinical Data

Both compounds have the bulk of their clinical evidence in Russian-language literature, which creates accessibility barriers for Western researchers. However, key findings have been translated, summarised, or replicated in accessible publications.

Semax Research Highlights

Semax cognitive research documents the compound's trajectory from ACTH fragment research through to clinical application. Major research themes include:

Acute stroke: Semax has been investigated in multiple Russian clinical trials for ischaemic stroke, where it reduced neurological deficit and improved recovery outcomes. A key mechanism is thought to be its BDNF-mediated neuroprotective effect in the peri-infarct zone.
Attention and working memory: Studies in healthy volunteers show improvements in attention span, working memory capacity, and psychomotor speed at intranasal doses of 0.1% solution (approximately 200–900 mcg per dose).
Optic nerve disease: Russian researchers have investigated Semax in optic neuritis and glaucoma, where BDNF upregulation in retinal ganglion cells is hypothesised as the protective mechanism.
Epilepsy: Semax has been studied as an adjunctive agent in epilepsy management, with some evidence for seizure threshold modulation through its effects on the enkephalin and GABA systems.

For a consolidated view of the published evidence, the Semax research overview compiles primary findings across both preclinical and clinical domains, including the stroke indication studies that represent Semax's strongest clinical evidence base.

Selank Research Highlights

Selank anxiolytic mechanisms covers the compound's anxiolytic pharmacology in detail. Key research themes include:

Generalised anxiety disorder: A 2005 double-blind, placebo-controlled trial (Semenova et al.) found Selank equivalent in anxiolytic efficacy to medazepam (a classical benzodiazepine) over four weeks, without inducing sedation, memory impairment, or the muscle relaxation typical of benzodiazepines.
Anxiety with asthenia: Selank has been specifically studied in patients presenting with anxiety comorbid with cognitive fatigue — a profile where benzodiazepines are generally contraindicated due to their sedative and amnestic effects. Selank produced anxiolytic benefit with concurrent improvement in memory and attention.
Stress resilience: Animal studies demonstrate that Selank reduces corticosterone response to stress, normalises stress-induced immune suppression, and prevents the hippocampal BDNF reductions that chronic stress produces.
PTSD-adjacent states: Russian researchers have examined Selank in post-traumatic anxiety states, where its combination of anxiolysis and BDNF normalisation is hypothesised to support the reconsolidation processes that allow trauma memories to be integrated rather than repeatedly reactivated.

Side Effect Profiles and Tolerability

Semax is generally well tolerated at research doses. The most commonly reported effects are mild nasal irritation from intranasal administration, transient headache (usually attributed to increased cerebral blood flow), and at higher doses, mild agitation or restlessness consistent with its stimulatory profile. There are no documented cases of dependence. Its half-life in plasma is short (minutes), but central effects persist longer — likely due to receptor-level and gene expression changes rather than continued peptide presence.

Selank has an even more benign tolerability profile in published research. It produces no sedation at standard doses, no amnestic effects (in contrast to benzodiazepines), no muscle relaxation, and no documented rebound anxiety upon discontinuation. This last point is significant: the absence of rebound is mechanistically explained by its receptor modulation pattern, which does not induce the compensatory GABA-A receptor downregulation that benzodiazepines produce with chronic use. Mild nasal irritation is similarly reported from intranasal use.

Use Cases: When to Select Each Compound

Semax Is Typically Appropriate When:

The research question involves cognitive enhancement under neurologically intact conditions — improving baseline focus, working memory, or processing speed
Motivation and drive are primary targets — the dopaminergic component makes Semax more relevant when low motivation is the limiting factor rather than anxiety
Neuroprotection in acute or subacute neurological injury contexts are under investigation
BDNF upregulation is a primary mechanistic target in the research design
The subject profile is one where stimulatory effects are appropriate and anxiety is not a significant comorbidity

Selank Is Typically Appropriate When:

Anxiety reduction without sedation or cognitive impairment is the primary goal
The subject profile involves stress-induced cognitive dysfunction — where cognitive deficits are secondary to anxiety or HPA axis dysregulation rather than primary
GABAergic modulation without benzodiazepine liabilities is the mechanistic target
Sleep architecture is a consideration — Selank may improve sleep quality without the REM suppression characteristic of classical benzodiazepines
Research involves withdrawal or discontinuation from benzodiazepines, where Selank's GABAergic support may ease the transition

Can Semax and Selank Be Combined?

The combination is documented in Russian clinical practice and has a mechanistic rationale. Semax's stimulatory, pro-dopaminergic profile can in some subjects produce a degree of activation that is mildly anxiogenic — particularly at higher doses. Selank's anxiolytic component can theoretically buffer this effect while preserving the cognitive-enhancing properties of Semax.

The more sophisticated framing is that the compounds address different bottlenecks: Semax increases the capacity for cognitive effort (substrate and trophic support), while Selank removes the interference that anxiety creates in that effort (noise reduction). In subjects where both capacity and noise are limiting factors, concurrent use addresses both simultaneously.

Research on the combination is less extensive than the individual compound literature, and human clinical data on combined administration is limited. Anecdotal reports from the Russian research community are generally positive, but this is not a substitute for controlled data. Researchers approaching a combination protocol should be attentive to individual responses and apply conservative initial dosing to each compound.

Practical Research Context

Both compounds are administered intranasally in research settings, which provides direct access to the olfactory-brain pathway and bypasses first-pass hepatic metabolism. Oral bioavailability is negligible for peptides of this size. The Semax research peptide and Selank research peptide are formulated specifically for intranasal administration.

Standard research doses for Semax range from 200–900 mcg intranasally per session, typically administered once or twice daily during a research period of 10–14 days, followed by a washout interval. Selank research doses are typically in the 250–1000 mcg range per intranasal administration, with similar cyclical protocols recommended to minimise receptor adaptation.

Both compounds are stable when refrigerated and are sensitive to repeated freeze-thaw cycles — a standard consideration for peptide storage in research settings.

Summary Comparison

| Feature | Semax | Selank | |---|---|---| | Structural origin | ACTH 4-7 analogue | Tuftsin analogue | | Primary mechanism | BDNF upregulation, dopaminergic | GABAergic modulation, anxiolytic | | Neurochemical tone | Stimulatory | Calming | | BDNF effect | Robust upregulation | Stress-normalisation | | Primary use case | Focus, motivation, neuroprotection | Anxiety, stress, calm cognition | | Side effect profile | Mild stimulation, nasal irritation | Minimal; no sedation | | Dependence potential | None documented | None documented | | Research depth | Substantial (stroke, cognition) | Substantial (anxiety, asthenia) |

The simplest framing: Semax is a cognitive accelerator with trophic and neuroprotective properties; Selank is a cognitive stabiliser that removes anxious interference from the cognitive process. They are not interchangeable, and the selection between them should be driven by the specific research question and subject profile rather than by a generalised preference for one over the other.

Both represent a pharmacological approach to cognitive modulation that is mechanistically distinct from small-molecule nootropics and from pharmaceutical stimulants — working through the brain's own trophic and regulatory systems rather than by directly overriding them.

Research references: Semenova TP et al. (2010) Selank and its analogue modulate the expression of genes related to the serotoninergic system, Dokl Biol Sci; Shadrina MI et al. (2010) Expression analysis of neurotrophic and growth factors in rats with experimental Alzheimer's disease after treatment with Semax, J Mol Neurosci; Semenova TP et al. (2005) Anxiolytic effects of Selank, Bull Exp Biol Med; Grigoriev VV et al. (2016) Semax modulates the expression of genes related to BDNF, Russ J Bioorg Chem.